AstraZeneca, Cephalon to pay to resolve Medicaid allegations: U.S.
WASHINGTON (Reuters) - AstraZeneca LP has agreed to pay $46.5 million and Cephalon Inc [TEVAE.UL] $7.5 million to resolve allegations that the two drug companies underpaid rebates owed under the Medicaid program, the U.S. Justice Department said on Monday. (Reporting by Eric Beech; Editing by Bill Trott)